Advanced Human Imaging (ASX:AHI) - CoFounder and Head of Strategy, Vlado Bosanac
CoFounder and Head of Strategy, Vlado Bosanac
Source: AHI
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Advanced Human Imaging (AHI) announces it will commence US presentations to raise US$15 million (nearly A$20 million)
  • The health imaging company is aiming to list on the NASDAQ, after filing a Form F-1 with the US Securities and Exchange Commission
  • AHI has now received conditional approval from the Nasdaq to list its American Depositary Shares (ADS)
  • The filing is based on an assumed ratio of one ADS to nine ordinary shares of AHI
  • On the market today, AHI was down 10.3 per cent and is trading at $1.01 per share

Advanced Human Imaging (AHI) has announced it will commence US presentations to raise US$15 million (nearly A$20 million).

The health imaging company is aiming to list on the NASDAQ, after filing a Form F-1 with the US Securities and Exchange Commission.

AHI has now received conditional approval from the Nasdaq to list its American Depositary Shares (ADS), each of which will represent a determined number of ordinary shares of AHI.

Final approval of the listing is subject to the company paying the Nasdaq listing fee and fulfilling the remaining conditions as needed by Nasdaq.

Additionally, AHI has submitted an updated public filing of a registration statement on Form F-1, with the US Securities and Exchange Commission.

The updated filings is for the proposed initial US public offering of its ADS. The number of securities to be sold and the price per ADS for the offering have been outlined in the F-1, based on a price range of US$7 to US$9 (about A$9 to A$12).

The filing was based on an assumed ADS to ordinary share ratio of one (1) ADS representing nine (9) ordinary shares of AHI.

On the market today, AHI was down 10.7 per cent, trading at $1.00 per share at 1:20 pm AEDT.

AHI by the numbers
More From The Market Online
The Market Online Video

Listen: From the Wire – Paradigm Biopharma CEO and Founder Paul Rennie

From The Wire: Senior markets reporter Jonathon Davidson sat down with Paradigm Biopharmaceuticals chief executive officer…
Lung imaging concept

Biotech lung imaging darling 4DX Medical back at $2.20/sh on Miami U contract

4DX Medical has seen its price jump back to $2.20/sh, as its next-gen lung imaging scan…
Chuffed bloke

Race Oncology’s placement-at-a-premium rewarded as shares jump +8%

Race Oncology has completed its recent A$3.2M placement – something that shareholders on the HotCopper forums…

Effective as an IV drug, a gel, and now an inhaler – Recce’s R327 can’t stop winning

Recce flagship antibacertial and anti-infective drug R327 has in a model that shows the drug could…